United States Food & Drug Administration (FDA) Grants
NEW YORK, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory...
Source: globenewswire.com
Steve Dabkowski News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Steve Dabkowski. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Steve Dabkowski Today - Breaking & Trending Today
Appendix 4C Quarterly Activity Report for Quarter Ended
NEW YORK, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for...
Source: globenewswire.com
United States Food & Drug Administration (FDA) Grants
FDA GRANTS MESOBLAST RARE PEDIATRIC DISEASE DESIGNATION FOR REVASCOR® (REXLEMESTROCEL-L) IN CHILDREN WITH CONGENITAL HEART DISEASE...
Source: globenewswire.com
Mesoblast Files for Orphan Drug and Pediatric Rare Disease
NEW YORK, Nov. 26, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory...
Source: globenewswire.com
Mesoblast Files for Orphan Drug and Pediatric Rare Disease Designations for Rexlemestrocel-L as Treatment for Severe Congenital Heart Disease
NEW YORK, Nov. 26, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has filed for orphan drug designation (ODD) and rare pediatric disease designation (RPDD) with the United States Food and Drug Administration (FDA) for its allogeneic cell therapy Revascor® (rexlemestrocel-L) in the treatment of the congenital heart disease hypoplastic left heart syndrome (HLHS). The filings were b
Source: yahoo.com